$17.87
+0.57 (+3.29%)
Last updated: May 31, 2026 08:35
Fundamentals Overview
Sarepta Therapeutics, Inc. is near the low of its 52-week range with premium valuation, trending upward today.
Valuation premium
Profitability
Risk (Beta)
0.26 — lower vol
Earnings & growth
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Analyst grade: B+ · Sentiment improving (5 upgrades)
Pressures (Sell):
3M vs S&P 500: -14.9%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 2, Equal Weight: 3, Market Perform: 1, Neutral: 3, Outperform: 6, Overweight: 3, Sell: 8, Underperform: 4.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-1,330.82; current price is $17.87. That’s a -7547.2% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 33.49 |
| PEG (TTM) | 0.27 |
| P/B (TTM) | 1.25 |
| P/S (TTM) | 0.86 |
| P/FCF (TTM) | 17.61 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 4.63 |
| Quick Ratio (TTM) | 2.62 |
| Cash Ratio (TTM) | 0.93 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 2.98% |
| Gross margin (TTM) | 62.39% |
| Operating margin (TTM) | -1.88% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for SRPT.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | maintain | Sell | Sell | 2026-04-16 |
| Citigroup | maintain | Sell | Sell | 2026-03-26 |
| Needham | maintain | Underperform | Underperform | 2026-03-26 |
| Oppenheimer | maintain | Outperform | Outperform | 2026-03-19 |
| Mizuho | maintain | Outperform | Outperform | 2026-03-13 |
| Citigroup | maintain | Sell | Sell | 2026-03-10 |
| HC Wainwright & Co. | maintain | Sell | Sell | 2026-03-02 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-02-27 |
| HC Wainwright & Co. | maintain | Sell | Sell | 2026-01-27 |
| Wedbush | maintain | Outperform | Outperform | 2026-01-23 |
| HC Wainwright & Co. | maintain | Sell | Sell | 2026-01-14 |
| Barclays | maintain | Equal Weight | Equal Weight | 2025-11-05 |
| Mizuho | upgrade | Neutral | Outperform | 2025-11-05 |
| Guggenheim | maintain | Buy | Buy | 2025-11-05 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-11-05 |
| Baird | maintain | Neutral | Neutral | 2025-11-04 |
| Piper Sandler | maintain | Neutral | Neutral | 2025-10-30 |
| BMO Capital | upgrade | Market Perform | Outperform | 2025-09-22 |
| Guggenheim | maintain | Buy | Buy | 2025-09-15 |
| Leerink Partners | maintain | Market Perform | Market Perform | 2025-09-09 |
| HC Wainwright & Co. | maintain | Sell | Sell | 2025-08-25 |
| B of A Securities | maintain | Underperform | Underperform | 2025-08-21 |
| B of A Securities | maintain | Underperform | Underperform | 2025-08-20 |
| Deutsche Bank | maintain | Sell | Sell | 2025-08-15 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-08-07 |
| Goldman Sachs | maintain | Neutral | Neutral | 2025-08-07 |
| Barclays | upgrade | Underweight | Equal Weight | 2025-07-30 |
| Barclays | upgrade | Underweight | Equal Weight | 2025-07-29 |
| Needham | maintain | Underperform | Underperform | 2025-07-29 |
| Oppenheimer | upgrade | Perform | Outperform | 2025-07-29 |